The adhesion molecule E-cadherin has been shown to influence malignant transformation of tumors, including local and distant metastases. We examined the expression of E-cadherin to determine its relationship to the development of metastasis in metastatic brain tumors. Immunohistochemistry for E-cadherin and Ki-67 was carried out in 76 formalin-fixed, paraffin-embedded archival specimens of metastatic brain tumors and in 14 corresponding available primary tumors from patients who received treatment for metastatic brain tumors. The primary tumors were mainly lung cancers (51.3%), followed by gastrointestinal tumors (28.9%). E-cadherin was expressed in 62 (81.5%) of 76 cases examined. In metastatic adenocarcinomas, a consistent tendency for E-cadherin expression was noted, regardless of the degree of differentiation or the extent of spread of the disease (P = 0.04). There was a direct correlation between E-cadherin expression and high MIB-1 index in all metastatic brain tumors (P = 0.0007). Pairwise analysis in 14 primary tumors and the corresponding metastatic specimens revealed high E-cadherin and MIB-1 staining in metastatic brain tumors. These results provide a unique association between E-cadherin, systemic metastasis, and proliferation potential in metastatic brain tumors.
Introduction
Brain tumor metastasis is a widely recognized cause of treatment failure and death in cancer patients. Currently, despite advances in treating metastatic brain tumors, the prognosis is still poor, with less than 10% survival at 90 weeks. 1 Control attempts broadly focus on preventing metastasis by adequate surgical treatment of primary tumors to ensure eradication of the primary source of metastasis. In the event of inadequacy, surgery is supplemented by radiation, chemotherapy, or both. Despite all these efforts, evidence from radiological follow-up shows strikingly higher incidences of brain metastatic tumors. Molecular and biological markers have proved their usefulness in ascertaining and predicting the capacity of primary tumors to metastasize to local or distant sites, a3 One of these molecules is E-cadherin, which has been extensively studied in many extracranial primary tumors. 4-6 E-cadherin is a calciumdependent homotypic cell adhesion molecule that plays an important role in the maintenance of tissue homogeneity and integrity. Underexpression of this molecule is responsible for the loose intercellular adhesion seen in most tumors, which enhances cell motility, invasion, and metastasis to surrounding lymph nodes. 7-~~ Consequently, underexpression of E-cadherin signifies a poor prognosis in patients with these tumors. 11-I6 E-cadherin is therefore expected to be down-regulated by the distantly metastasizing tumor cells. 17 However, Arnold et al., based on a small sample, showed consistent expression of E-cadherin in both metastatic and primary brain tumors, and therefore its role could not be established) s In this way it is expected for E-cadherin to influence tumor aggregation and possibly rededifferentiation, 19 or E-cadherin may be influencing the occurrence of hematogenic metastasis, the mechanism of which is still unknown. In the present study, we have employed a larger series of patients to delineate these characteristics of E-cadherin expression in metastatic brain tumors and to determine what influence it has on the genesis of brain metastases from primary tumors. We find that E-cadherin is expressed in metastatic brain tumors regardless of the source of the primary tumor, the histological grade or the extent of disease spread, and that expression of E-cadherin is associated with a high MIB-1 index.
Materials and methods

Patients and tissue samples
We retrospectively analyzed the medical records of 76 consecutive cases of metastatic brain tumor treated at Nagasaki University Hospital between 1983 and 2001. The male-tofemale ratio was 2:1, and the median age was 58.5 years (range, 30-80 years).
Formalin-fixed, paraffin-embedded specimens were retrieved from the archives of metastatic brain tumors of Nagasaki University Hospital. The biopsies were histologically classified according to the WHO classification of tumors. Corresponding primary tumor samples were available for 14 cases of metastatic brain tumor. Patient characteristics, including the extent of disease before the diagnosis of metastatic brain tumor, the radiological extent of brain metastases, treatment modality, and prognosis, were recorded. Solitary and multiple brain lesions were distinguished by MRI or CT scan. Multiple lesions refer to more than one MRI or CT lesion at least lcm apart or located in different regions. An extracranial metastasis lesion was considered present when there was involvement of organs other than that where the primary tumor was located.
Antibodies E-cadherin antibody was purchased from Santa Cruz Biotech (Delaware, CA, USA) and Ki-67 from DAKO (Glostrup, Denmark). Biotinylated antibodies were purchased from Vector Laboratories (Burlingame, CA, USA). All antibodies were stored and used according to the vendors' guidelines.
Immunohistochemistry
Four-micrometer sections prepared from paraffinembedded, formalin-fixed tissues were deparaffinized in xylene and then rehydrated in a graded series of alcohols. Subsequent steps of the procedure were performed according to our previously published protocol. 2~ Briefly, the slides were quenched in citrate buffer under microwave to retrieve the antigen. Intrinsic peroxidase activity was quenched by 3% HzO in methanol. Background staining was blocked by 1% bovine serum in phosphate-buffered saline. Primary antibodies against E-cadherin and Ki-67 antigen at 1:50 dilution were applied, and the slides were incubated at 4~ overnight. Immunohistochemical detection was carried out by the avidin biotin complex method using an ABC kit (Vectastain). The sections were finally colorized with diaminobenzidine and counterstained with hematoxylin. E-cadherin immunostaining of normal colon mucosa was employed as a standard control (Fig. 1) .
The percentage of immunoreactive cells was semiquantitatively analyzed by selecting at least four regions of strong staining, where cells were counted under highpower magnification (• to a total of 1000 cells, and the ratio of positively staining cells was calculated. Cutoff ratios were determined for E-cadherin staining scores, as shown in Table 1 . Two groups were selected E-cadherinpositive and E-cadherin-negative, the former including all staining positive for E cadherin, regardless of the staining score.
Statistical analysis
The chi-square test (ANOVA) was used to analyze differences among-the groups and the t-test to compare MIB-1 means; statistical significance was considered present when P < 0.05.
Results
The main source of brain metastases was lung cancer (51.32%), followed by gastrointestinal cancer (28.9%) and breast cancer (6%). Adenocarcinoma was the major histological type (86%) of metastatic brain tumor. The median latent period from the diagnosis of primary tumor to metastatic brain tumor was less than one month. Fifty-seven percent of cases documented spontaneous diagnosis of primary tumor and metastatic brain tumor, with the brain metastasis being most often first diagnosed.
The E-cadherin positivity rate in the metastatic brain tumors was 81.5%; the major staining category was mild to moderate, accounting for 39.5% of all staining metastatic brain tumors (Table 1 ). E-cadherin was found staining the cytoplasm in most tumors. This tendency was noted in most brain metastatic tumors, regardless of the location of the primary tumor (Table 1 ). The intensity of staining was mild to moderate, with no categorical difference with regard to degree of differentiation in adenocarcinoma. In the primary tumors, E-cadherin staining was noted in 12 of 14 cases (86%); the staining pattern was also cytoplasmic but was weaker and was observed in relatively isolated islands compared with their brain metastatic counterparts. The normal colon mucosa demonstrated E-cadherin staining in the cell membrane with strong intensity (Fig. 1) . Analysis of metastatic brain tumors showed a positive correlation between high MIB-1 labeling index and E-cadherin positivity (P = 0.0007). There was no difference in E-cadherin expression between single brain metastatic lesions and multiple lesions. Cases with exclusive brain metastases could not be separated from those with other accompanying hematogenic When metastatic brain adenocarcinomas were analyzed for E-cadherin expression and MIB-1 index, no difference in rate was noted with respect to histologic grade (P = 0.04; Table 2 ). There was a consistently high rate of E-cadherin expression with cytoplasmic staining, with high proliferation recorded (mean MIB-1, 44.27 -_ 29.23, 57.41 --;24.28, and 47.51 -+ 22.29 for well-differentiated, moderately differentiated, and poorly differentiated adenocarcinomas, respectively; P = 0.2). Pairwise analysis of 14 cases with brain metastases and primary tumor specimens showed a slightly higher rate of E-cadherin expression in metastatic brain tumors (P = 0.09), with stronger staining in brain metastatic lesions than in primary lesions. The MIB-1 index was higher in brain metastases than in primary tumors (Table 3) . Clinical studies analyzing the expression of E-cadherin in situ and in macrometastatic lesions such as those in lymph nodes and liver show reexpression of E-cadherin in the macrometastatic lesionsY There is even an emerging view of re-expressed E-cadherin in the growth and survival of these metastatic lesions. 24 ' 25 Because distantly metastasizing tumor cells are hematogenically transported, we expected that E-cadherin could influence seeding in the brain, which could affect the number of intracranial lesions. Contrary to ,this view, we found that expression of E-cadherin was not associated with multiple intracranial lesions. Moreover, the presence or absence of extracranial metastases at this stage of disease does not affect E-cadherin expression in metastatic brain lesions. This implies that E-cadherin expression may have a role in hematogenic transport of tumor cells rather than distant trapping and seeding of tumors. Indeed, the loss of E-cadherin has been documented to facilitate detachment of tumor emboli intravascularly. 26 Other studies have shown that E-cadherin-expressing cells dominate the intravascular compartment, thus supporting the speculation that only Ecadherin-expressing tumor cells survive during the intravas- 18 27 28 cular spread of tumors. ' ' We also know that mechanisms such as inherent adhesive actions to the capillary endothelium by cancer cells are involved in the propagation of tumor metastases. 29 Our series displays a paradoxical relationship between E-cadherin expression and high proliferative index. We speculate that E-cadherin may regulate cell proliferation in metastatic brain tumors. It is possible that the increased E-cadherin protein is related to overexpression or amplification of the gene itself. Alternatively, the increased E-cadherin could result from a global increase in protein turnover, which is a common secondary event in increased cell proliferation. Although both events are highly possible, future studies are necessary to prove the involvement of Ecadherin in the regulation of cell proliferation in metastatic brain tumors.
